Assessment of Pharmaceutical Protein–Ligand Pose and Affinity Predictions in CASP16
Proteins: Structure, Function, and Bioinformatics · 2026
DOI: 10.1002/prot.70061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, 2026. Verfasst von Michael K Gilson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Proteins, Computational Biology, Drug Discovery. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, US National Institute of General Medical Sciences (NIGMS/NIH), National Institutes of Health.
Abstract (Originalsprache)
The protein–ligand component of the 16th Critical Assessment of Structure Prediction (CASP16) challenged participants to predict both binding poses and affinities of small molecules to protein targets, with a focus on drug‐like compounds from pharmaceutical discovery projects. Thirty research groups submitted predictions for 229 protein–ligand pose targets and 140 affinity targets across five protein systems. Among the submitted predictions, template‐based pose‐prediction methods did particularly well, with the best groups achieving mean LDDT‐PLI values of 0.69 (scale of 0–1 with 1 best). For comparison, we also ran a set of automated baseline pose‐prediction methods, including ones using deep neural networks. Of these, AlphaFold 3 did particularly well, with a mean LDDT‐PLI of 0.8, thus outscoring the best CASP16 predictor. The CASP affinity predictions showed modest correlation with experimental data (maximum Kendall's τ = 0.42), well below the theoretical maximum possible given experimental uncertainty (~0.73). As seen in prior challenges, providing experimental structures did not improve affinity predictions in the second stage of the challenge, suggesting that the scoring functions used here are a key limiting factor. Overall, the accuracy achieved by CASP participants is similar to that observed in the prior Drug Design Data Resource (D3R) blinded prediction challenges. The present results highlight the progress and persistent challenges in computational protein–ligand modeling and provide valuable benchmarks for the field of computer‐aided drug design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
- SIB Swiss Institute of Bioinformatics, Basel, Switzerland.
- Biozentrum, University of Basel, Basel, Switzerland.
- Genome Center, University of California, Davis, California, USA.
ORCID-Profile: Michael K Gilson, Jerome Eberhardt, Peter Škrinjar, Janani Durairaj, Xavier Robin, Andriy Kryshtafovych
Förderung
- NIGMS NIH HHS
- US National Institute of General Medical Sciences (NIGMS/NIH)
- National Institutes of Health
Zitieren
APA
Gilson, M. K., Eberhardt, J., Škrinjar, P., Durairaj, J., Robin, X., & Kryshtafovych, A. (2026). Assessment of Pharmaceutical Protein–Ligand Pose and Affinity Predictions in CASP16. Proteins: Structure, Function, and Bioinformatics. https://doi.org/10.1002/prot.70061
Vancouver
Gilson MK, Eberhardt J, Škrinjar P, Durairaj J, Robin X, Kryshtafovych A. Assessment of Pharmaceutical Protein–Ligand Pose and Affinity Predictions in CASP16. Proteins: Structure, Function, and Bioinformatics. 2026. doi:10.1002/prot.70061
BibTeX
@article{Gilson2026,
author = {Gilson, Michael K and Eberhardt, Jerome and Škrinjar, Peter and Durairaj, Janani and Robin, Xavier and Kryshtafovych, Andriy},
title = {Assessment of Pharmaceutical Protein–Ligand Pose and Affinity Predictions in CASP16},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2026},
doi = {10.1002/prot.70061}
}
EUVIMED